Acuity Pharmaceuticals has appointed Denis O’Shaughnessy as its senior vice president of clinical development.
O’Shaughnessy was formerly senior vice president of clinical development and co-founder of Eyetech Pharmaceuticals, where he oversaw development of the wet age-related macular degeneration drug Macugen. Before this, he was director of clinical operations and department head at Hoffman-La Roche. He has also held positions at Cyanamid, Sandoz, Xoma, and Celltech.
“As we prepare to move into later stage trials with our lead compound bevasiranib, this experience should be of tremendous value in ensuring that our clinical program is optimally designed and executed,” Acuity President and CEO Dale Pfost said in a statement.